Announced Tue, 7 Jul · 19:16 IST
Name approved for proposed wholly-owned R&D subsidiary
Strategic Transactions View source PDF
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+1.2%1-day move
₹37.90
prior close
—
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————+1.2+1.6-1.1-1.1-2.7-3.7————
Up moveDown movePending
AI summary
Bacil Pharma has received approval from MCA's Central Registration Centre for the name 'Bacil Research and Development Private Limited' for its proposed wholly-owned subsidiary. The new entity will focus on research and development activities. The name approval is valid till 26 July 2026. Incorporation is still under progress and the company will make further disclosures once the Certificate of Incorporation is received.
Likely market impact
Sets up a dedicated R&D arm; positive for future growth but no financial details or capital commitment disclosed yet.